Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
CONCLUSION: Safety and efficacy of SB3 demonstrated in this real-world study were comparable with previous studies of reference trastuzumab.PMID:37899039 | DOI:10.1159/000534626 (Source: Oncology)
Source: Oncology - October 29, 2023 Category: Cancer & Oncology Authors: Changwan Jeon Su Hwan Kang Sung-Bae Kim Nam-Sun Paik Ilkyun Lee Seung Ki Kim Eun Young Kim Gil Soo Son Young Bum Yoo Kyung-Hee Lee JeongSoo Shin Sungil Ju Harah Jang Min Ho Park Source Type: research
Predictive value of recurrence of solid and micropapillary subtype in lung adenocarcinoma
CONCLUSION: This study suggested that histological subtypes such as micropapillary- or solid-predominant pattern are risk factors for recurrence in pathological stage 0-I lung adenocarcinoma and may be necessary adjuvant chemotherapy instead of uracil-tegafur.PMID:37899040 | DOI:10.1159/000530528 (Source: Oncology)
Source: Oncology - October 29, 2023 Category: Cancer & Oncology Authors: Nozomu Motono Takaki Mizoguchi Masahito Ishikawa Shun Iwai Yoshihito Iijima Hidetaka Uramoto Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Genetic profile of FOXO3 Single Nucleotide Polymorphism in colorectal cancer patients
CONCLUSION: This study suggests an association of increased risk of CRC with the rs4946936 polymorphism, but not with the rs2253310 polymorphism.PMID:37857267 | DOI:10.1159/000533729 (Source: Oncology)
Source: Oncology - October 19, 2023 Category: Cancer & Oncology Authors: Laraib Uroog Arshad Husain Rahmani Mohammed A Alsahli Saleh A Almatroodi Rauf Ahmad Wani M Moshahid Alam Rizvi Source Type: research
Viral infections and incidence of reactivations in chronic myeloid leukemia patients
Oncology. 2023 Oct 17. doi: 10.1159/000534266. Online ahead of print.ABSTRACTViral infections remain a significant problem for patients with chronic myeloid leukemia (CML) who undergo stem cell transplants (SCT). These infections often result from the reactivation of latent viruses. However, our understanding of the risk of viral reactivation in CML patients who have not undergone SCT is limited, and there is a scarcity of data on this topic. Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of CML, as it is highly successful and has transformed the prognosis of patients with CML. However, TKI may be assoc...
Source: Oncology - October 17, 2023 Category: Cancer & Oncology Authors: Mahmood B Aldapt Abdulrahman F Al-Mashdali Khaldun Obeidat Prem Chandra Mohamed Yassin Source Type: research
Viral infections and incidence of reactivations in chronic myeloid leukemia patients
Oncology. 2023 Oct 17. doi: 10.1159/000534266. Online ahead of print.ABSTRACTViral infections remain a significant problem for patients with chronic myeloid leukemia (CML) who undergo stem cell transplants (SCT). These infections often result from the reactivation of latent viruses. However, our understanding of the risk of viral reactivation in CML patients who have not undergone SCT is limited, and there is a scarcity of data on this topic. Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of CML, as it is highly successful and has transformed the prognosis of patients with CML. However, TKI may be assoc...
Source: Oncology - October 17, 2023 Category: Cancer & Oncology Authors: Mahmood B Aldapt Abdulrahman F Al-Mashdali Khaldun Obeidat Prem Chandra Mohamed Yassin Source Type: research
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases
CONCLUSIONS: At the six weeks of the pembrolizumab treatment, our risk model predicts the objective response rate precisely. Notably, those classified as 'poor risk'-marked by liver metastasis and a heightened NLR-should be considered for alternative therapy with a different mode of action, highlighting a critical decision point in treatment optimization.PMID:37839399 | DOI:10.1159/000534554 (Source: Oncology)
Source: Oncology - October 15, 2023 Category: Cancer & Oncology Authors: Kyosuke Nishio Takuya Higashio Kazumasa Komura Wataru Fukuokaya Takahiro Adachi Yosuke Hirasawa Takeshi Hashimoto Atsuhiko Yoshizawa Shuya Tsuchida Takuya Matsuda Takuya Tsujino Kazuki Nishimura Satoshi Tokushige Keita Nakamori Taizo Uchimoto Shutaro Yama Source Type: research
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases
CONCLUSIONS: At the six weeks of the pembrolizumab treatment, our risk model predicts the objective response rate precisely. Notably, those classified as 'poor risk'-marked by liver metastasis and a heightened NLR-should be considered for alternative therapy with a different mode of action, highlighting a critical decision point in treatment optimization.PMID:37839399 | DOI:10.1159/000534554 (Source: Oncology)
Source: Oncology - October 15, 2023 Category: Cancer & Oncology Authors: Kyosuke Nishio Takuya Higashio Kazumasa Komura Wataru Fukuokaya Takahiro Adachi Yosuke Hirasawa Takeshi Hashimoto Atsuhiko Yoshizawa Shuya Tsuchida Takuya Matsuda Takuya Tsujino Kazuki Nishimura Satoshi Tokushige Keita Nakamori Taizo Uchimoto Shutaro Yama Source Type: research
Outcomes and Feasibility of an Occupational Care Programme (TERRA) to Support Work Ability of Rare and Advanced Cancer Patients: A Report of 7 Cases
CONCLUSION: A multidisciplinary approach may further improve outcomes of occupational interventions supporting rare and advanced cancer patients. An effectiveness study to evaluate the outcomes and feasibility of the programme is deemed necessary.PMID:37827131 | DOI:10.1159/000534451 (Source: Oncology)
Source: Oncology - October 12, 2023 Category: Cancer & Oncology Authors: Floortje L Hosman Sascha C A Rozemeijer Amber D Zegers Annemarie Becker-Commissaris Heinz-Josef Kl ümpen Maurice J D L van der Vorst Linda Brom Saskia F A Duijts Source Type: research
